Table 3.

Risks of composite end-point natural Log-transformed Gd-IgA1 and ascending quartiles

					Hazard Ration (95% Confidence Interval) & p value
			Gd-IgA1,median (Range), U/ml	Unadjusted	Model 1 a	Model 2 b	Model 3 c
Composite endpoint
	Per 1SD lnGd-IgA1		312.5 (89.0–1442.0)	2.07 (1.53–2.78) 1.68×10−6	1.51 (1.16–1.97) 0.002	1.50 (1.15–1.96) 0.003	1.44 (1.11–1.88) 0.006
		Gd-IgA1 quartiles
		1	193.88 (89.0–237.0)	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
		2	272.51 (239.0–312.0)	2.63 (0.94–7.36) 0.066	2.71 (0.99–7.39) 0.052	2.73 (0.99–7.45) 0.051	2.47 (0.91–6.72) 0.077
		3	345.67 (313.0–406.0)	4.03(1.36–11.96) 0.012	3.74 (1.28–10.93) 0.016	3.72 (1.27–10.89) 0.016	3.86 (1.33–11.33) 0.013
		4	487.36 (408.0–1442.0)	6.76 (2.23–20.19) 0.001	5.18 (1.75–15.34) 0.003	5.29 (1.78–15.73) 0.003	4.76 (1.61–14.09) 0.005

Composite endpoint was defined as 50% decline of eGFR(n=29), ESRD(n=3) or death(n=2). The 2 deaths also had 50% decline of eGFR.

Abbreviation: LnGd-IgA1, Natural Log-transformed galactose-deficient IgA1. Unadjusted Model analyzed Gd-IgA1 as continuous data.

^aModel 1 adjusted for eGFR, proteinuria and hypertension (yes or no). Hypertension (yes or no) was analyzed as dichotomous data.

^bModel 2 adjusted for covariates in model 1 plus histological grading (mild and severe lesion group).The latter variable was analyzed as categorical data.

^cModel 3 adjusted for covariates in model 2 plus steroid use (yes or no). The latter variable was analyzed as dichotomous data.